Immunotherapy with inhibitors against the programmed death 1 (PD-1) receptor, its ligand (PD-L1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) has revolutionized the therapeutic scenario for patients with advanced NSCLC (aNSCLC) without driver mutations (25). Here, CTLA4 is linked to non-small cell lung carcinoma.